{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T04:10:27Z","timestamp":1771301427332,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1124\/dmd.117.078220","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T15:00:22Z","timestamp":1519830022000},"page":"532-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans"],"prefix":"10.1016","volume":"46","author":[{"given":"Caroline A.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zancong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Traci M.","family":"Ostertag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Girardet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gillen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.117.078220_bib1","doi-asserted-by":"crossref","unstructured":"Bardin T, Keenan R, Khanna P, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, So A (2015) Lesinurad, a selective uric acid reabsorption inhibitor, in combination with allopurinol: results from a phase III study in gout patients having an inadequate response to standard of care (CLEAR 2). Ann Rheum Dis 74:545.","DOI":"10.1136\/annrheumdis-2015-eular.1238"},{"key":"10.1124\/dmd.117.078220_bib2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/BOR.0000000000000028","article-title":"Definition of hyperuricemia and gouty conditions","volume":"26","author":"Bardin","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1124\/dmd.117.078220_bib3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.semarthrit.2015.05.005","article-title":"An open-label, 6 month study of allopurinol safety in gout: the LASSO study","volume":"45","author":"Becker","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1124\/dmd.117.078220_bib4","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.117.078220_bib5","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/art.27338","article-title":"Epidemiology of gout in women: fifty-two-year followup of a prospective cohort","volume":"62","author":"Bhole","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1124\/dmd.117.078220_bib6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/FPC.0b013e32810f2e58","article-title":"Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues","volume":"17","author":"Bi\u00e8che","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.117.078220_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/BOR.0000000000000146","article-title":"New medications in development for the treatment of hyperuricemia of gout","volume":"27","author":"Diaz-Torn\u00e9","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1124\/dmd.117.078220_bib8","first-page":"151","article-title":"Urate crystal deposition disease and gout - new therapies for an old problem - Chapter 11","volume":"49","author":"Girardet","year":"2014","journal-title":"Annu Rep Med Chem"},{"key":"10.1124\/dmd.117.078220_bib9","unstructured":"Heap G, Sosa MP (2012) Gout chart audit. BioTrends Research Group and Decision Resources Group."},{"key":"10.1124\/dmd.117.078220_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.bbrc.2005.08.190","article-title":"Structural diversity of human xenobiotic-metabolizing cytochrome P450 monooxygenases","volume":"338","author":"Johnson","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.117.078220_bib11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3109\/00498254.2011.563327","article-title":"N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases","volume":"41","author":"Kaivosaari","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.117.078220_bib12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bcp.12086","article-title":"Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT)","volume":"76","author":"Knights","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.117.078220_bib13","doi-asserted-by":"crossref","first-page":"8691","DOI":"10.1021\/acs.jmedchem.7b00510","article-title":"Glucuronides as potential anionic substrates of human cytochrome P450 2C8 (CYP2C8)","volume":"60","author":"Ma","year":"2017","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.117.078220_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/ard.2004.024091","article-title":"Gout epidemiology: results from the UK General Practice Research Database, 1990-1999","volume":"64","author":"Mikuls","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/dmd.117.078220_bib15","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1124\/dmd.108.021428","article-title":"Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines","volume":"36","author":"Nakamura","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078220_bib16","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1124\/dmd.109.027797","article-title":"A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding","volume":"37","author":"Nakayama","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078220_bib17","unstructured":"Ouk S, Gunic E, and Vernier J (2013) inventors. Thioacetate compounds, compositions and methods of use. U.S. patent 8,541,589 B2. 2013 Sep 24."},{"key":"10.1124\/dmd.117.078220_bib18","first-page":"104","article-title":"Efficacy and safety of lesinurad (RDEA594), a novel uricosuric agent, given in combination with allopurinol in allopurinol-refractory gout patients: randomized, double-blind, placebo-controlled, phase 2B study","volume":"70","author":"Perez-Ruiz","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/dmd.117.078220_bib19","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/annrheumdis-2015-207919","article-title":"Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol","volume":"75","author":"Perez-Ruiz","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/dmd.117.078220_bib20","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1021\/jm0109107","article-title":"Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID\/CPCA","volume":"44","author":"Ridderstr\u00f6m","year":"2001","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.117.078220_bib21","unstructured":"Saag K, Adler S, Bhakta N, Fung M, Kopicko J, Storgard C, and Bardin T (2014) Lesinurad, a novel selective uric acid reabsorption inhibitor, in two phase III clinical trials: Combination study of lesinurad in allopurinol standard of care inadequate responders (CLEAR 1 and 2). Presented at 2014 ACR\/ARHP Annual Meeting; November 14\u201319, 2014; Boston, MA. American College of Rheumatology, Atlanta, GA."},{"key":"10.1124\/dmd.117.078220_bib22","doi-asserted-by":"crossref","unstructured":"Saag K, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, Becker M (2015) Lesinurad, a selective uric acid reabsorption inhibitor, in combination with allopurinol: results from a phase III study in gout patients having an inadequate response to tandard of care (CLEAR 1). Ann Rheum Dis 74:540.","DOI":"10.1136\/annrheumdis-2015-eular.3273"},{"key":"10.1124\/dmd.117.078220_bib23","doi-asserted-by":"crossref","first-page":"9497","DOI":"10.1074\/jbc.M312516200","article-title":"Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site","volume":"279","author":"Schoch","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.117.078220_bib24","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.2147\/DDDT.S140658","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects","volume":"11","author":"Shen","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"Suppl 1","key":"10.1124\/dmd.117.078220_bib25","first-page":"S93","article-title":"RDEA594, a novel uricosuric agent, shows significant additive activity in combination with allopurinol in gout patients","volume":"89","author":"Shen","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.078220_bib26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13075-015-0624-3","article-title":"Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort","volume":"17","author":"Singh","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1124\/dmd.117.078220_bib27","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0090-9556(25)08612-X","article-title":"Covalent binding of zomepirac glucuronide to proteins: evidence for a Schiff base mechanism","volume":"18","author":"Smith","year":"1990","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078220_bib31","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.110.034173","article-title":"Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide","volume":"38","author":"Sawamura","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078220_bib28","first-page":"187","article-title":"Lesinurad (RDEA594), a novel investigational uricosuric agent for hyperuricemia and gout, blocks transport of uric acid induced by hydrochlorothiazide","volume":"70","author":"Tan","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/dmd.117.078220_bib29","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41598-017-00706-7","article-title":"Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout","volume":"7","author":"Tan","year":"2017","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.117.078220_bib32","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1021\/tx049900+","article-title":"A novel approach for predicting acyl glucuronide reactivity via Schiff base formation: development of rapidly formed peptide adducts for LC\/MS\/MS measurements","volume":"17","author":"Wang","year":"2004","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.117.078220_bib30","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562405459X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562405459X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.117.078220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:33:52Z","timestamp":1739903632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562405459X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S009095562405459X"],"URL":"https:\/\/doi.org\/10.1124\/dmd.117.078220","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.117.078220","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}